56 results about "Host protein" patented technology

The invention discloses a preparation method and application of recombinant human-like collagen. The recombinant human-like collagen is fusion protein of collagen and elastin. The preparation method comprises the following steps: taking constructed escherichia coli engineering bacteria, inducing expression of human-like collagen through high-density fermentation, performing high-pressure homogeneous cell disruption after tubular centrifugal collection of fermented thalli, performing acid regulation, flocculating and settling of cell debris and host protein, and controlling pH and conductivity of feed liquid to obtain the human-like collagen. Through ion exchange chromatography purification and ultrafiltration concentration replacement, a human-like collagen stock solution with the liquid phase purity of more than 98% is obtained, and the total yield is more than 75%. Through cell biological activity detection and analysis, the purified human-like collagen has remarkable biological activity of promoting cell migration and adhesion. The whole preparation process developed by the invention is simple and convenient in process, high in yield, easy to amplify and suitable for industrial production of the recombinant human-like collagen, and the prepared protein raw material can be widely applied to the fields of medical beauty and biological medicine.

The present invention relates to the field of biomedicine, and more particularly to a method for purifying an inactivated rabies virus vaccine. The method comprises the following steps: preparing an inactivated rabies virus ultrafiltration concentrate: purifying the inactivated rabies virus ultrafiltration concentrate by chromatography; the chromatography purification specifically comprises the following steps: column cleaning: loading a composite filler into a chromatography column, connecting an AKTA to the chromatography column, cleaning, sterilizing, and setting aside; chromatography operation: equilibrating the chromatography column with PBS buffer; sample loading: loading the inactivated rabies virus ultrafiltration concentrate into the chromatography column, eluting with an eluent, and collecting the eluate corresponding to the absorption peak at an ultraviolet wavelength of 280 nm, which is the purified inactivated rabies virus vaccine; column cleaning; and results showing that the residual protein content is as low as 5.0 ng / ml, the antigen content can reach above 16.0 IU / ml, the host protein removal rate can reach above 99%, and the antigen content recovery rate can reach above 86%.

The invention relates to a high-temperature-resistant feruloyl esterase liquid as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) constructing a reaction system: suspending recombinant microorganism thalli for expressing high-temperature-resistant feruloyl esterase in a buffer solution with the pH value of 7.0-9.0; (2) ultrasonic cracking and thermal purification: heating the reaction system to 70-85 DEG C under the condition of ultrasonic crushing, and keeping the temperature for 1-8 hours; carrying out structural destruction on the microbial thalli by utilizing ultrasound so as to release intracellular high-temperature-resistant feruloyl esterase, and carrying out denaturation and precipitation on host impure protein by utilizing the thermal stability difference between the high-temperature-resistant feruloyl esterase and the host impure protein; after the high-temperature-resistant feruloyl esterase is subjected to heat treatment in the step (2), the catalytic activity is kept at the temperature of 60 DEG C or above; and (3) obtaining an enzyme solution, namely centrifuging the reaction body fluid subjected to the ultrasonic treatment and the heat treatment in the step (2), and collecting supernate, so as to obtain the high-temperature-resistant feruloyl esterase solution.

The application is a virus and host protein interaction prediction method based on a densely connected convolutional network, comprising the following steps: step 1, preprocessing data; step 2, using a Skip-Gram model in Word2Vec and One-Hot encoding to obtain embedding vectors of amino acids; step 3, constructing a densely connected convolutional network for feature extraction according to a word embedding matrix of the protein; step 4, obtaining average RPM-PSSM feature descriptors through a PSSM feature matrix; step 5, constructing a fully connected neural network for feature extraction according to the feature descriptors; step 6, performing feature fusion through a concatenate operation, and finally using the trained model for prediction. The application performs feature extraction on different features, contains protein evolution information and physicochemical properties, local key information and long-range dependence in the sequence, and better improves the prediction accuracy.

The invention belongs to the field of biology, and particularly relates to construction of a recombinant Seneca virus strain with Seneca virus 2B protein translation block site mutation. The 26th lysine (K) of the 2B protein is found to be a key site for inhibiting the translation of the host protein for the first time, and after the 26th K of the 2B protein is mutated into the alanine (A), the translation retardation phenomenon of the host protein is obviously weakened; secondly, the 26th K of the 2B protein is mutated into A to construct infectious clone, and the recombinant Seneca virus strain rSVA-2B K26A with 2B protein translation retardation site mutation is successfully rescued and obtained, compared with wild type SVA, after the rSVA-2B K26A infects host cells, the translation retardation phenomenon of the host cells is weakened, the expression level of host antiviral inflammatory cytokines is enhanced, and the expression level of the recombinant Seneca virus strain rSVA-2B K26A is improved. The Seneca virus vaccine strain can be used as a potential vaccine candidate strain, and a foundation is laid for developing a novel prevention and control strategy aiming at the Seneca virus.

The invention discloses a rabbit milk host protein detection kit. The rabbit milk host protein detection kit comprises an elisa plate coated with a capture antibody and a detection antibody marked by HRP (horse radish peroxidase), the capture antibody is an antibody obtained by performing Protein G affinity chromatography on serum obtained after sheep is immunized by using non-transgenic skimmed rabbit milk as an immunogen; the detection antibody is obtained by performing immunoaffinity chromatography on serum obtained after sheep is immunized by using non-transgenic skimmed rabbit milk as an immunogen. The kit disclosed by the invention is applied to detection of rabbit milk host protein residues in recombinant protein medicines expressed by a transgenic rabbit breast bioreactor, and has the characteristics of high specificity, high sensitivity, high detection efficiency, capability of simultaneously detecting a plurality of samples, simple used equipment, convenience in operation and low detection cost, and the limit of quantitation reaches 5ng / mL.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR / Cas9 and RNAi / RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

The invention relates to an improved sample preparation method for LC-MS / MS analysis that enables an efficient isolation, purification and identification of protein contaminants, such as host cell proteins (HCPs) as process-related impurities generated during the production of biopharmaceuticals, such as monoclonal antibodies (mAbs).

The invention provides application of 7, 8-dihydroxyflavone in preparation of a medicine for treating diseases caused by herpes virus infection, and belongs to the technical field of biological medicine. The 7, 8-dihydroxy flavone can be used for remarkably inhibiting infection of herpes simplex viruses HSV-1 and HSV-2, and has broad-spectrum anti-HSV activity. According to the present invention, the HSV virus protein expression can be significantly inhibited by pretreating the virus with the 1, 7, 8-dihydroxyflavone and treating the cells after the virus adsorption, the virus plaque formation can be reduced, and the dose dependence can be provided; experiments show that the 7, 8-dihydroxyflavone plays the anti-herpes simplex virus activity mainly through targeting host protein fructose-diphosphate aldolase A. The 7, 8-dihydroxyflavone has the anti-herpes simplex virus activity. Mouse in-vivo experiments prove that the 7, 8-dihydroxyflavone can significantly improve the survival rate of HSV-1 mice, improve the weight reduction trend and reduce the virus titer of lung tissues; meanwhile, mouse genital organ lesions caused by HSV-2 infection can be remarkably relieved, and the weight of infected mice is improved. Therefore, the compound 7, 8-dihydroxyflavone is expected to be developed into a candidate drug for treating the herpes simplex virus.

The invention discloses a targeted nutrient source mining method based on beef cattle intestinal type-host gene interaction, particularly relates to the field of biological information data processing, and is used for solving the problems that existing nutrient source development lacks molecular mechanism verification and is poor in targeting. The method comprises the following steps: firstly, dividing nutrition-associated intestinal types based on microbiome and transcriptome data, and constructing a co-expression network to screen host co-expression specific genes driven by the specific intestinal types; then, establishing a flora metabolite ligand set and host protein receptor model, executing molecular conformation search and Gibbs free energy calculation, and screening high-activity targeting effect factors based on physical affinity; and finally, traversal matching and quantitative screening are carried out on the natural raw material liquid chromatography-mass spectrometry data by using the targeted effect factors, and a targeted nutrition source recommendation list aiming at the specific intestine type is generated. According to the method, multi-omics correlation analysis and molecular thermodynamics verification are fused, and an accurate development closed loop from micromechanism analysis to macroscopic raw material matching is constructed.

The invention belongs to the technical field of biology, and particularly relates to application of CD14 gene / protein as a target spot to screening of drugs for preventing or treating African swine fever virus infection, the inventor uses host protein CD14 as a research object to explore the influence of the host protein CD14 on ASFV infected host cells, and research results show that the CD14 protein can promote adsorption, internalization and replication of ASFV, and the CD14 gene / protein can be used for preparing drugs for preventing or treating ASFV infection. The siRNA, the antibody and the recombinant protein of the CD14 can inhibit ASFV infected cells, and vaccines or drugs for preventing or treating African swine fever virus infection can be screened or anti-African swine fever CD14 knockout pigs can be screened by taking the CD14 gene / protein as a target spot. The invention enriches the cognition of the host protein for regulating and controlling ASFV infection, provides theoretical support for the research and development of safe and effective ASF vaccines, and has important significance for the clinical treatment and prevention and control of African swine fever.

The invention provides a chicken FSHR (follicle stimulating hormone receptor) polyclonal antibody as well as a preparation method and application thereof. A prokaryotic expression target sequence of the chicken FSHR polyclonal antibody is as shown in SEQ ID NO: 1. The preparation method of the chicken FSHR polyclonal antibody is the preparation method of the chicken FSHR polyclonal antibody, and comprises the following steps: (1) recombining an FSHR gene into a prokaryotic expression vector, constructing a prokaryotic recombinant expression plasmid, transforming the prokaryotic recombinant expression plasmid into a host cell, performing induced expression, and purifying host protein; and (2) animal immunization, blood collection, serum separation, purification and titer determination. The polyclonal antibody can effectively recognize the endogenous chicken FSHR antigen and the FSHR protein expressed in chicken tissues, has high specific recognition capability, and lays a foundation for researching the structure and function of the chicken FSHR protein.

The invention discloses a nucleic acid molecule for inhibiting Zika virus, a pharmaceutical composition containing the nucleic acid molecule and application. The invention develops an anti-virus strategy for realizing the target host protein based on the RNA structure by changing the bottom-layer anti-virus logic. The MSI1 binding site in the nucleic acid molecule is highly conserved in all Zika virus strains, and the nucleic acid molecule has wide applicability. Meanwhile, the nucleic acid molecule can target an MSI1 high-expression region (namely virus-susceptible tissue), the problem of poor tissue specificity in existing delivery is solved, and the nucleic acid molecule is higher in targeting property, so that the nucleic acid molecule can cope with nervous system infection and pregnancy infection. In addition, the sequence design is relatively simple, and based on natural RNA sequence optimization, the modification demand is reduced, the natural affinity is high, and the chemical modification dependence is greatly reduced.

The invention discloses application of carfilzomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of nipah virus M protein, the carfilzomib is used for inhibiting a host proteasome path, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and the effect is good. At present, most of research and development of virus medicines and vaccines are designed or modified aiming at viruses, a new thought is provided for research and development of medicines and vaccines in the future, and a new application is also provided for Carfilzomib.

The invention discloses an affinity purification process for human serum albumin and a DARPin dimer ligand, the DARPin dimer comprises a first DARPin monomer and a second DARPin monomer, and the first DARPin monomer and the second DARPin monomer both have a four-segment structure of N-cap, IR1, IR2 and C-cap; the amino acid sequences of the first DARPin monomer and the second DARPin monomer are selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 in a sequence list; the amino acid sequences of the first DARPin monomer and the second DARPin monomer have at least 90%-98% sequence identity with any one amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5, and maintain specific binding activity to human serum albumin. According to the present invention, through the N-cap, IR1, IR2 and C-cap four-segment type DARPin dimer design, the convection column matrix is optimized so as to obtain the novel ligand with high affinity and high specificity on the human serum albumin, and the non-specificity of the host protein and the similar structure impurities is significantly reduced;

Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and / or nasal administration of the pharmaceutical composition.

Provided herein is a synthetic polypeptide derived from a high mobility group cassette 1 (HMGB1) host protein that can both disrupt bacterial biofilm and prevent the formation of neutrophil extracellular traps (NETs). Also provided herein are methods of disrupting abnormal or excessive NET formation, which are particularly suitable for treating high risk populations, the composition can be used for people suffering from infection of SARS CoV-2, septicemia, autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, type I diabetes mellitus and small vasculitis), autoinflammatory diseases (such as gout and inflammatory bowel disease) and metabolic diseases (such as type 2 diabetes mellitus and obesity).

Dengue virus (DENV) is a mosquito-borne flavivirus responsible for dengue fever. Studies have shown that DENV interacts with metabolic pathways, in particular the glycolysis is increased in DENV-infected cells. However, the dependence of DENV on this pathway has not been investigated in details. The inventors identified an interaction between the non-structural protein 3 (NS3) of DENV and GCKR, a host protein that regulates the liver-specific hexokinase GCK. NS3 expression alone was found to increase glucose consumption and lactate secretion in an hepatic cell line expressing GCK. The inventors observed that GCKR interaction with GCK decreases DENV replication, supporting the role of NS3 as an inhibitor of GCKR function. By targeting NAD(H) biosynthesis with the antimetabolite 6-Amino-Nicotinamide (6-AN), the inventors decreased cellular glycolytic activity and inhibited DENV replication in hepatic cell. The present invention thus relates to the use of inhibitors of NAD biosynthesis for the treatment of dengue virus infections.

The application discloses a kind of multilocular hydatid Em Preparation method of 6B protein and application thereof in preparation of anti-host inflammatory response preparation. By protein structure modeling, molecular docking technology, it is confirmed that Em 6B can be combined with host 26S proteasome key subunit with high affinity, affect the assembly of host proteasome in vivo, and then intervene the activity of NF-κB signal pathway, so as to regulate host inflammatory response. Through animal experiment, it is shown that recombinant Em 6B intervention can significantly alleviate the colon injury of inflammatory bowel disease mice, regulate the expression level of pro-inflammatory and anti-inflammatory factors, and improve the survival rate of sepsis mice, and no obvious toxic side effects are observed. The application opens up a new path for developing anti-inflammatory preparations using parasite-host immune interaction natural molecules, and provides a kind of anti-host inflammatory response biological preparation technical scheme with novel mechanism of action and good biological safety, which has good application potential in the prevention and treatment of human and livestock inflammatory diseases.

This invention discloses a multilocular echinococcosis larva. In Preparation method of -6B protein and its application in the preparation of anti-host inflammatory agents. Through protein structure modeling and molecular docking technology, the preparation method was confirmed. In -6B can bind with high affinity to a key subunit of the host 26S proteasome, affecting the assembly of the proteasome in the host and thus interfering with the activity of the NF-κB signaling pathway, thereby regulating the host inflammatory response. Animal experiments have shown that recombinant... In -6B intervention significantly alleviated colonic damage in mice with inflammatory bowel disease, regulated the expression levels of pro-inflammatory and anti-inflammatory factors, and improved the survival rate of septic mice, with no obvious toxic side effects observed. This invention opens up a new pathway for developing anti-inflammatory agents using natural molecules that interact with the parasite's immune system, and provides a novel mechanism of action and biosafety for anti-host inflammatory biological agents, showing great potential for application in the prevention and treatment of inflammatory diseases in humans and livestock.

Pathogens developing resistance to available drugs are of main concern in various diseases, including cryptococcosis and tuberculosis. Hence there is a need for therapeutics with novel mechanisms of action. Described herein are compositions and methods for treating infections (e.g., fungal infections) caused by microbes (e.g., fungi) comprising inteins. An intein is a moving protein element inside a host protein. Splicing off intein from the host protein is required to maturate and activate the host protein. Calcimycin (CMN) is used as an intein splicing inhibitor to block intein splicing of the Prp8 protein of fungal pathogen C. neoformans and C. gattii the causative agents of cryptococcosis, to treat patients.

This invention provides rice OsLHCA3 The uses of genes and their application in breeding virus-resistant rice, the above OsLHCA3 The nucleotide sequence of the gene is shown in SEQ ID NO.1. This invention utilizes transgenic technology to achieve overexpression in rice. OsLHCA3 This gene can significantly enhance rice's resistance to RSV. The mechanism lies in... OsLHCA3 The protein recruits the RSV motility protein NSvc4 to chloroplasts, interfering with the interaction between NSvc4 and the host protein OsREM1.4, thereby inhibiting the intercellular motility function of NSvc4. This invention provides a new gene resource for RSV-resistant rice breeding and has important application prospects.

The invention belongs to the technical field of molecular biology and immunology, and provides a host protein for inhibiting porcine epidemic diarrhea virus replication. The purpose of inhibiting the porcine epidemic diarrhea virus is achieved by screening medicaments capable of promoting Nox4 expression or improving protein activity, or the purpose of obtaining the Nox4 inhibitor is achieved by screening medicaments capable of inhibiting Nox4 expression or protein activity. Host cells with Nox4 genes knocked out or host cells in a Nox4 inhibitor environment are infected by porcine epidemic diarrhea viruses, so that the antigen of the inactivated vaccine is produced. The invention provides a new target for prevention and control of the porcine epidemic diarrhea virus, can be applied to virus-host interaction theory research of the porcine epidemic diarrhea virus and drug production of the porcine epidemic diarrhea virus, and has important significance in research and development of new drugs and vaccines.

The invention relates to the technical field of biology, and discloses an antiviral polypeptide and application thereof. According to the antiviral polypeptide provided by the invention, the host protein ARF4 is innovatively taken as a target spot, the purpose of resisting virus infection or relieving pathological lesions caused by virus infection is achieved by adjusting the function of the host protein, and the antiviral polypeptide has an excellent antiviral effect. The host protein is selected as a target spot, so that the antiviral polypeptide provided by the invention can well avoid the problem of vaccine or antiviral drug failure caused by strong RNA virus variability, and has higher stability and wider application prospect.

This invention relates to the field of biotechnology, specifically to a method for elucidating the interaction complex between the BTVNS2 protein and host cells. The method involves constructing an initial list of host proteins through cross-validation using affinity purification-mass spectrometry and biotinylate proximity labeling-mass spectrometry. Weighted scoring and ranking are then performed based on quantitative mass spectrometry data and functional relevance. Binding characteristics are validated and quantified intracellularly and extracellularly using immunoprecipitation and biophysical techniques, respectively. The complex is assembled in vitro, and its high-resolution three-dimensional structure is resolved using single-particle cryo-electron microscopy. This invention addresses key problems in existing technologies, such as incomplete capture of interacting proteins, high false-positive rates, blind functional screening, and difficulty in obtaining samples suitable for high-resolution structural analysis due to reliance on single methods. It systematically identifies key host factors and ultimately reveals the precise structure of the interaction interface at the atomic level, providing a foundation for understanding viral replication mechanisms and developing antiviral strategies.

The application discloses a host protein BRAP peptide segment and application thereof in coronavirus research and treatment, and specifically comprises the following steps: identifying a BRAP peptide segment with specific interaction with a SARS-CoV-2 CoV-Y domain, developing a method for identifying the interaction between the peptide segment and the coronavirus in vitro, preparing a drug for inhibiting SARS-CoV-2-induced host inflammatory response by using the peptide segment, constructing a model for screening anti-SARS-CoV-2 drugs, and establishing an in-vitro model for studying the SARS-CoV-2 infection mechanism, so as to provide a theoretical basis and technical support for in-depth understanding of the pathogenic mechanism of the coronavirus, development of new anti-virus drugs and treatment strategies. The peptide segment has interaction with the CoV-Y domain, and the dissociation constant Kd of the interaction is 12.67+ / -0.2 mu M, and the stoichiometric ratio is 1:1.

The invention discloses an affinity chromatography method for purifying human growth hormone and a DARPin dimer ligand. The DARPin dimer comprises a first DARPin monomer and a second DARPin monomer which are connected through a connecting peptide or a disulfide bond; each DARPin monomer is provided with a four-section type structure of an N-cap, a first internal repeated module IR1, a second internal repeated module IR2 and a C-cap; the amino acid sequence of the DARPin monomer is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 in a sequence list, and the amino acid sequence of the DARPin monomer has 90%-98% sequence identity with any amino acid sequence selected from the list. According to the present invention, through the design of the DARPin dimer ligand having the N-cap, the first internal repeating module IR1, the second internal repeating module IR2 and the C-cap four-segment structure, and the directed random mutation of the IR1 / IR2 region, the novel ligand having high affinity and high specificity on the human growth hormone is obtained, and the non-specific binding of the host protein and the structure-similar impurities is significantly reduced;

The invention belongs to the technical field of plant genetic engineering, and particularly relates to application of corn casein kinase ZmCK2 beta or a coding gene thereof in regulation and control of corn resistance to corn yellow mosaic virus. The host protein ZmCK2 beta interacting with the CP is obtained through screening, it is found that ZmCK2 beta and ZmCK2 alpha can interact inside and outside a plant body, and CP and ZmCK2 alpha only interact in the plant body; the ZmCK2 beta and the ZmCK2 alpha-ZmCK2 beta complex in the plants are respectively silenced, and after the MaYMV is inoculated, the virus accumulation amount on the silenced plants is reduced, which indicates that the silenced ZmCK2 beta and the silenced ZmCK2 alpha-ZmCK2 beta complex can inhibit infection; a ZmCK2 beta-knockout transgenic corn strain is constructed, and it is found that the virus accumulation amount on the plant is also reduced after ZmCK2 beta is knocked out. The invention provides a scientific basis for deeply analyzing the MaYMV pathogenic mechanism, and lays a theoretical foundation for formulating a virus prevention and control strategy.

The invention provides an L protein mutated foot and mouth disease virus recombinant strain as well as a construction method and application thereof, and belongs to the technical field of biotechnology. The invention relates to an L protein mutated foot and mouth disease virus recombinant strain, wherein L protein is mutated L protein with 18th, 28th and 39th amino acids mutated or deleted. The invention proves that the overexpression of the host protein POLR2H inhibits the replication of the FMDV, and the L protein is degraded through a proteasome pathway so as to inhibit the virus replication; key amino acid sites (18, 28 and 39) in the FMDV L protein are mutated to construct the foot and mouth disease virus recombinant strain which is not inhibited by host protein POLR2H for replication, and the recombinant virus can be stably passaged, has the characteristic of high virus titer on BHK-21 cells, improves the virus titer and antigen yield, can be used for preparing FMDV vaccines, and can be used for preparing FMDV vaccines. Good application prospects are realized.

The invention provides a method for purifying an antibody by using Protein A affinity chromatography and application of the method, and the method comprises the following steps: loading a supernatant solution to be purified into a Protein A affinity chromatography medium, and sequentially carrying out leaching and elution for three times to obtain the purified antibody. The method comprises the following steps: adding sodium caprylate into a supernatant solution; or sodium caprylate, a combination of sodium caprylate and NaCl and a combination of sodium caprylate and Arg-HCl are added into the leacheate, so that the host protein and esterase removal capability of Protein A affinity chromatography is improved. According to the antibody purification method, the host protein and esterase removal capacity of Protein A affinity chromatography can be effectively enhanced on the premise that the recovery rate is guaranteed and the polymer removal capacity is not reduced, the technological process of the method is stable and controllable, the method can effectively reduce impurity residues in drugs, and the method is suitable for industrial production. The effective guarantee is provided for the safety and the stability of the medicine.